Ocular Therapeutix, Inc. (OCUL) AI Stock Analysis

Ocular Therapeutix, Inc. is a biopharmaceutical company based in Bedford, Massachusetts, focused on formulating, developing, and commercializing therapies for eye diseases using its bioresorbable hydrogel-based technology. Its commercial portfolio includes ReSure Sealant, an ophthalmic device to prevent corneal wound leaks following cataract surgery, and DEXTENZA, a dexamethasone insert for post-surgical ocular inflammation, pain, and allergic conjunctivitis. The company is advancing pipeline candidates including OTX-TKI for wet age-related macular degeneration, OTX-TIC for open-angle glaucoma, and OTX-CSI and OTX-DED for dry eye disease, while collaborating with partners such as Regeneron Pharmaceuticals and AffaMed.

Revenue expanded from $43.5M in FY2021 to $63.7M in FY2024 before dropping 18.7% to $51.8M in FY2025. Despite revenue contraction in FY2025, gross margin remained high at 87.3%, down from 91.2% in FY2024 and 91.0% in FY2023. Escalating research and development expenses, which reached $197.1M in FY2025 compared to $50.1M in FY2021, led to an operating margin of -521.0% and an annual net loss of -$265.9M. For the trailing twelve months ended June 30, 2026, revenue stood at $52.1M with quarterly revenue growth of 0.1% year-over-year, while operating margin was -609.3% and diluted EPS was -$1.40.

As of June 30, 2026, Ocular Therapeutix held $598.6M in cash and short-term investments against total debt of $79.4M, resulting in net cash of $519.3M. Total assets were $671.3M and shareholders' equity stood at $520.0M, supported by a current ratio of 13.11 and a debt-to-equity ratio of 0.15. In FY2025, operating cash flow was -$204.9M and free cash flow was -$216.9M, which included capital expenditures of $12.0M. The company raised $1.6M through share issuance in FY2025, with its share count increasing 173.0% over 5 years.

Trading at $6.87 as of October 16, 2026, Ocular Therapeutix has a market capitalization of $1.51B and an enterprise value of $1.68B. Its price-to-sales multiple is 29.0x and EV-to-revenue is 32.2x, substantially above the median of its US-listed Healthcare peers of 4.1x sales. The company's price-to-book ratio stands at 4.2x. Over the past year, the stock fell 43.7% and dropped 38.6% over five years, significantly lagging the S&P 500, which gained 16.8% over one year and 83.0% over five years.

Wall Street coverage consists of 8 Strong Buy and 4 Buy ratings, with zero Hold, Sell, or Strong Sell recommendations. The mean price target of $26.00 implies upside of 278.5% over the last close of $6.87. For the fiscal year ending December 31, 2026, analysts estimate revenue of $52.8M and an EPS of -$1.44. For FY2027, 6 analysts project revenue to increase 93.1% to $102.0M, alongside an EPS estimate of -$1.48. Ocular Therapeutix beat EPS estimates in 2 of the last 4 quarters, with next earnings scheduled for November 3, 2026.

This page is an AI-written research summary of Ocular Therapeutix, Inc. (OCUL). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: OCUL income statement, OCUL balance sheet, OCUL key metrics, OCUL analyst forecast, OCUL chart. See the OCUL stock overview for the latest quote and news.